SAN FRANCISCO, California. February 8, 2013 – Xalud Therapeutics, Inc., a private biotechnology company, announced that it had been awarded a $690,000 SBIR grant from the National Institute of Neurological Disorders and Stroke, a division of the National Institutes of Health. The grant, which will be paid over…